复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析*

doi:10.3969/j.issn.1672-5069.2019.06.026

Abstract

Abstract: Objective To analyze the improvement of clinical symptoms and hepatic fibrosis in patients with primary biliary cirrhosis（PBC） by compound Biejiaruangan tablets. Methods A total of 78 patients with PBC were admitted to our hospital between January 2016 and December 2017,and they were divided into the control group （n=37） and observation group（n=41）. Patients in the control group were treated with ursodeoxycholic acid（UDCA） capsules,and patients in the observation group were treated with combination of compound Biejiaruangan tablets and UDCA for 24 weeks. trol group. The scores of PBC-40 scale,liver function tests and serum type III procollagen n-terminal peptide （PC-III）,laminin （LN） and type IV collagen （IV-C） were compared between the two groups. Results At the end of 24-week observation,the fatigue score in the observation group was （18.5±5.5）,the itching score was （4.7±1.3）,and social intercourse score was （14.4±3.9）,all significantly lower than（25.5±7.0）,（5.1±1.5）,and（19.2±4.6）（P<0.05） before treatment,and the scores of fatigue and social intercourse in observation group were significantlylower than （23.2±5.5） and （18.1±4.9） in control group（P<0.05）;serum levels of ALT,AST,GGT and AKP in observation group were（90.2±17.6） U/L,（81.5±14.8） U/L,（187.1±16.3） U/L,（117.5±28.1） IU/L,significantly lower than（133.6±24.6） U/L,（124.9±14.9） U/L,（350.4±18.9） U/L and （484.1±52.3） IU/L before treatment （P<0.05）,or than（101.3±15.3） U/L,（95.3±18.0） U/L,（199.8±15.7） U/L,（152.6±21.3） IU/L,respectively,in control group（P<0.05）;serum PC-III,LN and IV-C levels in observation group were （120.9±20.0） μg/L,（123.4±16.9） μg/L,（92.5±18.5）μg/L,significantly lower than （193.5±30.0） μg/L,（160.4±20.1） μg/L,（180.2±21.3） μg/L before treatment （P<0.05）,or than （131.6±21.5） μg/L,（136.8±15.4） μg/L,（109.4±10.0） μg/L,respectively,in the control group（P<0.05）. Conclusion Compound Biejiaruangan tablets has a good curative effect on patients with PBC,it could alleviate clinical symptoms and improve liver fibrosis.

Key words: Primary biliary cirrhosis, Compound Biejiaruangan tablets, Hepatic fibrosis, Therapy

Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets[J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.

References

[1] Invernizzi P,Leung P S C,Xiong M,et al. Primary biliary cirrhosis. Semin Liver Dis,2014,34(03):253-254.
[2] Hirschfield G M,Gershwin M E.The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol Mech,2013,8(8):303-330.
[3] Carbone M,Mells G F,Pells G,et al.Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology,2013,144(3):560-569,e7.
[4] Boberg K M,Wislff T,Kjllesdal K S,et al.Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther,2013,38(7):794-803.
[5] 姚云洁,杨才兴,巫继. 恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎患者疗效观察. 实用肝脏病杂志,2015,18(4):356-359.
[6] Sun CY,MA X.An excerpt of EASL clinical practice guidelines:the diagnosis and management of patients with primary biliary cholangitis (2017). J Hepatol,2017,33(10):1888-1894.
[7] Raszeja-Wyszomirska J,Kucharski R,Zygmunt M,et al.The impact of fragility fractures on health-related quality of life in patients with primary sclerosing cholangitis. Hepat Mon,2015,15(4):1-7.
[8] Boonstra K,Beuers U,Ponsioen C Y.Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis:a systematic review. J Hepatol,2012,56(5):1180-1188.
[9] Bowlus C L,Gershwin M E.The diagnosis of primary biliary cirrhosis. Autoimmun Rev,2014,13(4-5):441-444.
[10] Dilger K,Hohenester S,Winkler-Budenhofer U,et al.Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol,2012,57(1):133-140.
[11] Wu G,He H,Li H,et al.Clinical effect of combination therapy with Fufang Biejia Ruangan tablet and entecavir in patients with hepatitis B virus-related cirrhosis. J Hepatol,2014,22(8):604-608.
[12] Song Y N,Chen J,Cai F F,et al.A metabolic mechanism analysis of Fuzheng-Huayu formula for improving liver cirrhosis with traditional Chinese medicine syndromes. Acta Pharmacol Sin,2017,39(6):942-951.
[13] Huang L.Clinical efficacy of biejiaruangan compound tablets in treatment of primary biliary cirrhosis. J Hepatol,2015,31(2):181-184.
[14] Domanski J P,Harrison S A.The AST to ALT ratio:a pattern worth considering. Curr Hepat Rep,2013,12(1):47-52.
[15] Weiting L U,Xinghuo J,Haiyan G.Clinical features of primary biliary cirrhosis:a clinical analysis of 70 cases. J Hepatol,2013,29(12):926-928.
[16] Yang N H,Yuan G S,Zhou Y C,et al.Entecavir combined with Fufang Biejia Ruangan tablet in treatment of chronic hepatitis B patients with liver fibrosis:96-week efficacy analyses. J Southern Med Univ,2016,36(6):775-779.
[17] Xu C H,Meng D M,Lyu S L,et al.The detection and clinical significance of hepatic fibrosis index. Chin J Exp Clin Virol,2010,24(1):50-52.
[18] 周瑾,陈香美,魏日胞,等. 复方鳖甲软肝片方对TGF-β_1诱导的肾间质成纤维细胞增殖及分泌细胞外基质的影响.中国中西医结合肾病杂志,2014,15(5):381-384.
[19] 高翔,尚双艳.复方鳖甲软肝片对二乙基亚硝胺所致原发性肝癌大鼠肝组织PCNA和α-SMA表达的影响.实用肝脏病杂志,2018,21(4):553-556.
[20] Guo S G,Zhang W,Jiang T,et al.Influence of serum collected from rat perfused with compound Biejiaruangan drug on hepatic stellate cells. World J Gastroenterol,2004,10(10):1487-1494.
[21] 胡翠兰,刘纯钢,袁艳梅.复方鳖甲软肝片联合复方甘草酸苷治疗代偿期肝硬化患者疗效观察.实用肝脏病杂志,2014,17(2):192-193.

Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[2]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[3]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[4]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[5]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[6]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[7]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[8]	Ma Yaqiong, Li Zhilan, Xia Bing.. Early administration of enteral nutrition and microecological agents in patients with hepatic encephalopathy [J]. Journal of Practical Hepatology, 2019, 22(6): 892-895.
[9]	Feng Wenguang, Jiang Wei, Song Guojun.. PPV-guided fluid therapy in patients with hepatolithiasis underwent partial hepatectomy [J]. Journal of Practical Hepatology, 2019, 22(6): 912-915.
[10]	Li Qiuxi, Jia Jianfeng, Huang Rui.. Clinical value of segmental pedicle hepatectomy and B-ultrasound-guided hepatectomy in the treatment of patients with hepatolithiasis [J]. Journal of Practical Hepatology, 2019, 22(6): 916-919.
[11]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[12]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[13]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[14]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[15]	Song Haiyan, Chen Xi, Zhang Junfei, et al. Application of vorionazole in the treatment of patients with liver failure complicated by pulmonary fungal infection [J]. Journal of Practical Hepatology, 2019, 22(5): 676-679.